After completing her neurology training at Hospital Ramon y Cajal in Madrid, Dr Delia Chaverri entered as staff Neurologist at the Hospital Carlos III. There she combined her duty as general neurologist with a special involvement with ALS patients. With Dr J. Mora, she established the first ALS Unit in Spain. Devoted mainly to patient care, she has participated in a large number of ALS international clinical trials. In 2014, the Hospital Carlos III merged with Hospital La Paz, forming a single institution where she has been coordinating the ALS unit since 2016. More than 300 patients are treated regularly at the unit by a high level multidisciplinary team.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.